125 related articles for article (PubMed ID: 7681480)
1. Non-nucleoside inhibitors of HIV-1 reverse transcriptase: molecular modeling and X-ray structure investigations.
Schäfer W; Friebe WG; Leinert H; Mertens A; Poll T; von der Saal W; Zilch H; Nuber B; Ziegler ML
J Med Chem; 1993 Mar; 36(6):726-32. PubMed ID: 7681480
[TBL] [Abstract][Full Text] [Related]
2. Crystal structure of nevirapine, a non-nucleoside inhibitor of HIV-1 reverse transcriptase, and computational alignment with a structurally diverse inhibitor.
Mui PW; Jacober SP; Hargrave KD; Adams J
J Med Chem; 1992 Jan; 35(1):201-2. PubMed ID: 1370694
[No Abstract] [Full Text] [Related]
3. Mechanism of inhibition of HIV-1 reverse transcriptase by nonnucleoside inhibitors.
Spence RA; Kati WM; Anderson KS; Johnson KA
Science; 1995 Feb; 267(5200):988-93. PubMed ID: 7532321
[TBL] [Abstract][Full Text] [Related]
4. The structure of HIV-1 reverse transcriptase complexed with 9-chloro-TIBO: lessons for inhibitor design.
Ren J; Esnouf R; Hopkins A; Ross C; Jones Y; Stammers D; Stuart D
Structure; 1995 Sep; 3(9):915-26. PubMed ID: 8535785
[TBL] [Abstract][Full Text] [Related]
5. Substituted naphthalenones as a new structural class of HIV-1 reverse transcriptase inhibitors.
Alam M; Bechtold CM; Patick AK; Skoog MT; Gant TG; Colonno RJ; Meyers AI; Li H; Trimble J; Lin PF
Antiviral Res; 1993 Oct; 22(2-3):131-41. PubMed ID: 7506510
[TBL] [Abstract][Full Text] [Related]
6. Hologram quantitative structure-activity relationships investigations of non-nucleoside reverse transcriptase inhibitors.
Pungpo P; Hannongbua S; Wolschann P
Curr Med Chem; 2003 Sep; 10(17):1661-77. PubMed ID: 12871115
[TBL] [Abstract][Full Text] [Related]
7. A mutation in reverse transcriptase of bis(heteroaryl)piperazine-resistant human immunodeficiency virus type 1 that confers increased sensitivity to other nonnucleoside inhibitors.
Dueweke TJ; Pushkarskaya T; Poppe SM; Swaney SM; Zhao JQ; Chen IS; Stevenson M; Tarpley WG
Proc Natl Acad Sci U S A; 1993 May; 90(10):4713-7. PubMed ID: 7685109
[TBL] [Abstract][Full Text] [Related]
8. Crystal structures of 8-Cl and 9-Cl TIBO complexed with wild-type HIV-1 RT and 8-Cl TIBO complexed with the Tyr181Cys HIV-1 RT drug-resistant mutant.
Das K; Ding J; Hsiou Y; Clark AD; Moereels H; Koymans L; Andries K; Pauwels R; Janssen PA; Boyer PL; Clark P; Smith RH; Kroeger Smith MB; Michejda CJ; Hughes SH; Arnold E
J Mol Biol; 1996 Dec; 264(5):1085-100. PubMed ID: 9000632
[TBL] [Abstract][Full Text] [Related]
9. Molecular modeling studies of HIV-1 reverse transcriptase nonnucleoside inhibitors: total energy of complexation as a predictor of drug placement and activity.
Kroeger Smith MB; Rouzer CA; Taneyhill LA; Smith NA; Hughes SH; Boyer PL; Janssen PA; Moereels H; Koymans L; Arnold E
Protein Sci; 1995 Oct; 4(10):2203-22. PubMed ID: 8535257
[TBL] [Abstract][Full Text] [Related]
10. Quantitative structure-activity relationships and comparative molecular field analysis of TIBO derivatised HIV-1 reverse transcriptase inhibitors.
Hannongbua S; Pungpo P; Limtrakul J; Wolschann P
J Comput Aided Mol Des; 1999 Nov; 13(6):563-77. PubMed ID: 10584215
[TBL] [Abstract][Full Text] [Related]
11. Structural flexibility of non-nucleoside HIV-1 reverse transcriptase inhibitor: 9-Cl TIBO as explained by potential energy surface and (13)C and (1)H NMR calculations, based on ab initio and density functional study.
Saen-Oon S; Hannongbua S; Wolschann P
J Chem Inf Comput Sci; 2003; 43(5):1412-22. PubMed ID: 14502474
[TBL] [Abstract][Full Text] [Related]
12. Comparative molecular field analysis (CoMFA) and docking studies of non-nucleoside HIV-1 RT inhibitors (NNIs).
Barreca ML; Carotti A; Carrieri A; Chimirri A; Monforte AM; Calace MP; Rao A
Bioorg Med Chem; 1999 Nov; 7(11):2283-92. PubMed ID: 10632038
[TBL] [Abstract][Full Text] [Related]
13. Quantitative structure-activity relationship studies on anti-HIV-1 TIBO derivatives as inhibitors of viral reverse transcriptase.
Gupta SP; Garg R
J Enzyme Inhib; 1996 Aug; 11(1):23-32. PubMed ID: 9204393
[TBL] [Abstract][Full Text] [Related]
14. HIV resistance to reverse transcriptase inhibitors.
De Clercq E
Biochem Pharmacol; 1994 Jan; 47(2):155-69. PubMed ID: 7508227
[No Abstract] [Full Text] [Related]
15. Enzymatic properties and sensitivity to inhibitors of human immunodeficiency virus type 1 (HIV-1) reverse transcriptase with Glu-138-->Arg and Tyr-188-->His mutations.
Zhang H; Vrang L; Bäckbro K; Unge T; Noréen R; Oberg B
Antiviral Res; 1994 May; 24(1):43-57. PubMed ID: 7524439
[TBL] [Abstract][Full Text] [Related]
16. Crystallographic analysis of the binding modes of thiazoloisoindolinone non-nucleoside inhibitors to HIV-1 reverse transcriptase and comparison with modeling studies.
Ren J; Esnouf RM; Hopkins AL; Stuart DI; Stammers DK
J Med Chem; 1999 Sep; 42(19):3845-51. PubMed ID: 10508433
[TBL] [Abstract][Full Text] [Related]
17. Imidazo[1,2-a]pyridin-3-amines as potential HIV-1 non-nucleoside reverse transcriptase inhibitors.
Bode ML; Gravestock D; Moleele SS; van der Westhuyzen CW; Pelly SC; Steenkamp PA; Hoppe HC; Khan T; Nkabinde LA
Bioorg Med Chem; 2011 Jul; 19(14):4227-37. PubMed ID: 21700466
[TBL] [Abstract][Full Text] [Related]
18. Colorimetric assays for evaluation of the mode of action of human immunodeficiency virus type 1 non-nucleoside reverse transcriptase inhibitors.
Shao X; Rytting AS; Ekstrand DH; Vrang L; Källander CF; Gronowitz JS
Antivir Chem Chemother; 1998 Mar; 9(2):167-76. PubMed ID: 9875388
[TBL] [Abstract][Full Text] [Related]
19. Structure of HIV-1 RT/TIBO R 86183 complex reveals similarity in the binding of diverse nonnucleoside inhibitors.
Ding J; Das K; Moereels H; Koymans L; Andries K; Janssen PA; Hughes SH; Arnold E
Nat Struct Biol; 1995 May; 2(5):407-15. PubMed ID: 7545077
[TBL] [Abstract][Full Text] [Related]
20. Development of nonnucleoside HIV reverse transcriptase inhibitors.
Tucker TJ; Lumma WC; Culberson JC
Methods Enzymol; 1996; 275():440-72. PubMed ID: 9026654
[No Abstract] [Full Text] [Related]
[Next] [New Search]
